Name: AcLysValCit-PABC-DMAE-SW-163D
Brand: BOC Sciences
Rating: 5 (1 reviews)

Size

Price

Stock

Quantity

$--

In stock

Canonical SMILES

CC1CC12C(=O)OCC(C(=O)NC(C(=O)N(C3C(SCC(C(=O)N2C)N(C(=O)C(NC(=O)C(COC(=O)C4(CC4C)N(C3=O)C)NC(=O)C5=NC6=CC=CC=C6C=C5O)C)C)SC)C)C)NC(=O)C7=NC8=CC=CC=C8C=C7OC(=O)N(C)CCN(C)C(=O)OCC9=CC=C(C=C9)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C

InChI

InChI=1S/C85H113N19O22S2/c1-44(2)63(98-68(108)56(91-49(7)105)26-19-20-32-86)71(111)95-57(27-21-33-88-81(87)120)67(107)92-53-30-28-50(29-31-53)40-125-82(121)99(8)34-35-100(9)83(122)126-62-37-52-23-16-18-25-55(52)94-65(62)73(113)97-59-42-123-79(118)84(38-45(84)3)103(12)76(116)60-43-128-78(127-14)66(102(11)75(115)48(6)90-70(59)110)77(117)104(13)85(39-46(85)4)80(119)124-41-58(69(109)89-47(5)74(114)101(60)10)96-72(112)64-61(106)36-51-22-15-17-24-54(51)93-64/h15-18,22-25,28-31,36-37,44-48,56-60,63,66,78,106H,19-21,26-27,32-35,38-43,86H2,1-14H3,(H,89,109)(H,90,110)(H,91,105)(H,92,107)(H,95,111)(H,96,112)(H,97,113)(H,98,108)(H3,87,88,120)/t45-,46-,47-,48-,56+,57-,58+,59+,60-,63-,66+,78-,84-,85-/m0/s1

Solubility

10 mm in DMSO

Appearance

Solid

Shelf Life

0-4°C for short term (days to weeks), or -20°C for long term (months).

Shipping

-20°C (International: -20°C)

Storage

Store at -5°C,keep in dry and avoid sunlight.

Form

Solid

AcLysValCit-PABC-DMAE-SW-163D is a complex compound primarily used in targeted drug delivery systems. Here are some key applications of AcLysValCit-PABC-DMAE-SW-163D:

Cancer Therapy: AcLysValCit-PABC-DMAE-SW-163D can be conjugated with cytotoxic drugs to form antibody-drug conjugates (ADCs) that specifically target cancer cells. This targeted approach minimizes damage to healthy cells and reduces side effects associated with traditional chemotherapy. The compound acts as a linker, enabling the precise release of the therapeutic agent within the tumor microenvironment.

Immunotherapy: In immunotherapy, AcLysValCit-PABC-DMAE-SW-163D can be used to enhance the delivery and effectiveness of immune-modulating drugs. By attaching immunotherapeutic agents to this linker, the drug can be more accurately directed to immune cells or cancer cells. This helps in boosting the body's immune response against tumors and improving treatment outcomes.

Bioconjugation Research: AcLysValCit-PABC-DMAE-SW-163D serves as a versatile linker in bioconjugation studies, facilitating the development of new drug delivery systems. Researchers can use it to link a wide variety of therapeutic molecules to targeting moieties, such as antibodies or peptides. This broadens the range of diseases that can be targeted with precision medicine approaches.

Diagnostic Imaging: The compound can also be applied in diagnostic imaging, where it aids in the targeted delivery of imaging agents. By conjugating imaging molecules with AcLysValCit-PABC-DMAE-SW-163D, clinicians can achieve more precise localization of disease sites using advanced imaging techniques. This improves the accuracy of diagnostics and enables better monitoring of disease progression and treatment efficacy.

What is AcLysValCit-PABC-DMAE-SW-163D?

AcLysValCit-PABC-DMAE-SW-163D is a peptide-based cytotoxic ADC payload designed for targeted drug delivery. It incorporates a cleavable linker and a potent DMAE cytotoxin, facilitating selective release in tumor cells for preclinical oncology studies.

7/5/2019

We would like to know how AcLysValCit-PABC-DMAE-SW-163D works in ADCs.

In ADCs, the Val-Cit-PABC linker is cleaved by intracellular proteases after endocytosis, releasing DMAE-SW-163D. The cytotoxin then disrupts essential cellular processes, inducing apoptosis and enabling potent tumor-targeted activity.

15/7/2019

Could you provide information on the research applications of AcLysValCit-PABC-DMAE-SW-163D?

This compound is used to study ADC linker cleavage efficiency, intracellular payload release, and tumor-specific cytotoxicity. It supports preclinical evaluation of ADC design and therapeutic potential in oncology models.

5/8/2018

Could you kindly advise what chemical characteristics define AcLysValCit-PABC-DMAE-SW-163D?

AcLysValCit-PABC-DMAE-SW-163D consists of a peptide-based cleavable linker (Val-Cit-PABC) connected to a DMAE cytotoxin. Its modular design facilitates conjugation to antibodies and selective intracellular release of the payload.

16/3/2021

Good afternoon! What safety precautions are recommended for AcLysValCit-PABC-DMAE-SW-163D?

Due to its high cytotoxicity, AcLysValCit-PABC-DMAE-SW-163D requires strict handling protocols, including PPE, containment, and proper waste management to ensure safety during ADC research and conjugation experiments.

28/6/2020

— Dr. David Miller, Senior ADC Researcher (USA)

AcLysValCit-PABC-DMAE-SW-163D delivered by BOC Sciences showed high purity and stability.

5/8/2018

— Dr. James Mitchell, Principal Scientist (USA)

We incorporated AcLysValCit-PABC-DMAE-SW-163D into our ADC program and were impressed with the consistency of quality from BOC Sciences. The linker-toxin conjugate worked seamlessly in our experiments.

28/6/2020

— Ms. Clara Evans, Regulatory Affairs Manager (UK)

The AcLysValCit-PABC-DMAE-SW-163D material was delivered promptly with comprehensive documentation. It gave us confidence to move forward with regulatory filings.

16/3/2021

— Mr. Daniel Foster, R&D Chemist (Germany)

High batch-to-batch reproducibility of AcLysValCit-PABC-DMAE-SW-163D ensured our screening results were reliable. Their service exceeded expectations.

7/5/2019

— Dr. Maria Lopez, Bioconjugation Specialist (Spain)

The purity of AcLysValCit-PABC-DMAE-SW-163D exceeded our internal QC benchmarks. BOC Sciences demonstrated strong expertise in ADC linker-toxin synthesis.

— Mr. Robert Klein, Senior Scientist (Switzerland)

AcLysValCit-PABC-DMAE-SW-163D proved highly effective in conjugation studies. The technical support team provided by BOC Sciences was extremely helpful.

15/7/2019